IN
Item 9 Labs Corp.
INLB · OTC
$0.00 +0.00% (+$0.00)
Market Cap $70.2K
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
3/9Valuation
100 /100
Cheap P/S 0.00x
P/B 0.00x
P/E N/A
Growth
100 /100
Growing Rev. growth 63.98%
Book val. growth 102.51%
EPS growth N/A
Profitability
13 /100
Weak Gross margin 33.61%
FCF margin 35.45%
Net margin 143.14%
Quality
3 /100
Poor ROIC 25.60%
Asset turnover 0.20x
ROA 28.12%
Debt
61 /100
Moderate Debt/Equity 0.45x
Net debt/EBITDA -1.22x
Current ratio 0.09x
Stability
1 /100
Unstable Beta 0.14x
Profitable years 0
Rev. volatility 86.24%
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o INLB
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Jeffrey I. Rassas
Employees
97
Headquarters
Phoenix
Prihajajoči dogodki
02 DEC.
Earnings
Upcoming earnings report